Your browser doesn't support javascript.
loading
Toward a Single-Dose Cure for Buruli Ulcer.
Thomas, Sangeeta S; Kalia, Nitin Pal; Ruf, Marie-Thérèse; Pluschke, Gerd; Pethe, Kevin.
Afiliação
  • Thomas SS; NTU Institute for Health Technologies (HealthTech NTU), Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore.
  • Kalia NP; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
  • Ruf MT; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
  • Pluschke G; Clinical Microbiology Division, CSIR-IIIM, Jammu and Kashmir, India.
  • Pethe K; Swiss Tropical and Public Health Institute, Basel, Switzerland.
Antimicrob Agents Chemother ; 64(9)2020 08 20.
Article em En | MEDLINE | ID: mdl-32631818
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium ulcerans / Úlcera de Buruli Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium ulcerans / Úlcera de Buruli Idioma: En Ano de publicação: 2020 Tipo de documento: Article